Vaccitech


Vaccitech Limited is a biotechnology company developing seasonal Influenza vaccines and immunotherapies for prostate cancer. The company's platform includes Chimpanzee Adenovirus Oxford and Modified Vaccinia Ankara, two viral vectors which mimic viral disease in human cells and elicit T cell responses to pathogens and tumours. The company was founded in 2016 as a University spin-off by Sarah Gilbert and Adrian V. S. Hill at the Jenner Institute, University of Oxford.
Vaccitech has been financed and supported by Google Ventures, Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation. investment in vaccitech has included over £20m of series A round funding.